Immunohistochemical study of psoriatic plaques and perilesional skin in psoriasis vulgaris patients: A pilot study

Morar,Iulia-Ioana; Tabăran,Flaviu-Alexandru; Mocan,Teodora; Jianu,Elena-Mihaela; Orăsan,Meda-Sandra; Pop,Alexandra-Dana; Orăsan,Remus-Ioan

doi:10.3892/etm.2019.7596

Immunohistochemical study of psoriatic plaques and perilesional skin in psoriasis vulgaris patients: A pilot study

Authors:
- Iulia-Ioana Morar
- Flaviu-Alexandru Tabăran
- Teodora Mocan
- Elena-Mihaela Jianu
- Meda-Sandra Orăsan
- Alexandra-Dana Pop
- Remus-Ioan Orăsan
View Affiliations

Affiliations: Department of Pathophysiology, ‘Iuliu Haţieganu’ University of Medicine and Pharmacy, 400012 Cluj-Napoca, Romania, Department of Pathological Anatomy, University of Agricultural Sciences and Veterinary Medicine, Faculty of Veterinary Medicine, 400372 Cluj-Napoca, Romania, Department of Physiology, ‘Iuliu Haţieganu’ University of Medicine and Pharmacy, 400012 Cluj-Napoca, Romania, Department of Histology, ‘Iuliu Haţieganu’ University of Medicine and Pharmacy, 400012 Cluj-Napoca, Romania
Published online on: May 21, 2019 https://doi.org/10.3892/etm.2019.7596
Pages: 888-894
Copyright: © Morar et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Psoriasis vulgaris, a chronic inflammatory skin disorder, is the result of immune mediated processes, genetic background and environmental factors. Prolactin and the vascular endothelial growth factor seem to play a key role in psoriasis pathogenesis regarding hyperproliferation of epidermal keratinocytes and dermal vascular ectasia. The aim of the study was to investigate the expression of tumor necrosis factor‑α (TNF‑α), vascular endothelial growth factor receptor 2 (VEGFR2) and prolactin receptor (PRLR) in psoriatic skin by immunohistochemical analysis and to evaluate the correlation with disease severity. Two skin biopsies, psoriatic lesion and perilesional skin, obtained by punch biopsy from 19 nontreated psoriasis patients were examined in hematoxylin and eosin staining and immunohistochemistry (IHC) for TNF‑α, VEGFR2 and PRLR. The indirect IHC reaction was carried out automatically and visualized by 3,3'‑diaminobenzidine (DAB) technique. The average number of DAB‑positive cells and the intensity of cell staining were quantified on a predefined scale. The results show a significant difference in the quantity and distribution of TNF‑α positive cells in the two sample groups. In psoriatic plaque skin, an increased expression of TNF‑α was found in the perivascular dermis and epidermic keratinocytes. In perilesional skin the immunostaining was predominant in the basal layer keratinocytes, while in psoriatic plaque, all the layers were positively marked, with stronger expression at the base. A statistically significant difference was found between the intensity of the immunostaining in the two types of tissue. Positive cells for VEGFR2 and PRL were identified in the basal layer keratinocyte cells (VEGFR2), sweat glands and hair outer shaft sheath (PRLR), without significant differences between the two types of samples. Our findings confirm the importance of TNF‑α in psoriasis pathogenesis and a positive correlation with lesions severity. No significant differences were found for VEGFR2 and PRLR, but additional studies are necessary to establish their role.

View Figures

View References

1	Parisi R, Symmons DP, Griffiths CE and Ashcroft DM; Identification, Management of Psoriasis and Associated ComorbidiTy (IMPACT) project team, : Global epidemiology of psoriasis: A systematic review of incidence and prevalence. J Invest Dermatol. 133:377–385. 2013. View Article : Google Scholar : PubMed/NCBI
2	Batani A, Brănișteanu DE, Ilie MA, Boda D, Ianosi S, Ianosi G and Caruntu C: Assessment of dermal papillary and microvascular parameters in psoriasis vulgaris using in vivo reflectance confocal microscopy. Exp Ther Med. 15:1241–1246. 2018.PubMed/NCBI
3	Deng Y, Chang C and Lu Q: The inflammatory response in psoriasis: A comprehensive review. Clin Rev Allergy Immunol. 50:377–389. 2016. View Article : Google Scholar : PubMed/NCBI
4	Boda D, Negrei C, Nicolescu F and Balalau C: Assessment of some oxidative stress parameters in methotrexate treated psoriasis patients. Farmacia. 62:704–710. 2014.
5	Raţiu MP, Purcărea I, Popa F, Purcărea VL, Purcărea TV, Lupuleasa D and Boda D: Escaping the economic turn down through performing employees, creative leaders and growth driver capabilities in the Romanian pharmaceutical industry. Farmacia. 59:119–130. 2011.
6	Negrei C, Caruntu C, Ginghina O, Burcea Dragomiroiu GT, Toderescu CD and Boda D: Qualitative and quantitative determination of methotrexate polyglutamates in erythrocytes by high performance liquid chromatography. Rev Chim. 66:607–610. 2015.
7	Negrei C, Ginghină O, Căruntu C, Burcea Dragomiroiu GT, Jinescu G and Boda D: Investigation relevance of methotrexate polyglutamates in biological systems by high performance liquid chromatography. Rev Chim. 66:766–768. 2015.
8	Caruntu C, Boda D, Dumitrascu G, Constantin C and Neagu M: Proteomics focusing on immune markers in psoriatic arthritis. Biomarkers Med. 9:513–528. 2015. View Article : Google Scholar
9	Kanda N, Hau CS, Tada Y and Watanabe S: Prolactin may promote the development of psoriasis: Reawakened issue. J Clin Exp Dermatol Res. 4:10001982013.
10	Foitzik K, Langan EA and Paus R: Prolactin and the skin: A dermatological perspective on an ancient pleiotropic peptide hormone. J Invest Dermatol. 129:1071–1087. 2009. View Article : Google Scholar : PubMed/NCBI
11	Kanda N, Shibata S, Tada Y, Nashiro K, Tamaki K and Watanabe S: Prolactin enhances basal and IL-17-induced CCL20 production by human keratinocytes. Eur J Immunol. 39:996–1006. 2009. View Article : Google Scholar : PubMed/NCBI
12	Olteanu R, Constantin MM, Zota A, Dorobantu D, Constantin T, Serban ED, Balanescu P, Mihele D and Gheuca-Solovastru L: Original clinical experience and approach to treatment study with interleukine 12/23 inhibitor in moderate-to-severe psoriasis patients. Farmacia. 64:918–921. 2016.
13	Sunnemark D, Ulfgren AK, Örn A and Harris RA: Cytokine production in hearts of Trypanosoma cruzi-infected CBA mice: Do cytokine patterns in chronic stage reflect the establishment of myocardial pathology? Scand J Immunol. 44:421–429. 1996. View Article : Google Scholar : PubMed/NCBI
14	Charles CA, Romanelli P, Martinez ZB, Ma F, Roberts B and Kirsner RS: Tumor necrosis factor-alfa in nonhealing venous leg ulcers. J Am Acad Dermatol. 60:951–955. 2009. View Article : Google Scholar : PubMed/NCBI
15	Ettehadi P, Greaves MW, Wallach D, Aderka D and Camp RD: Elevated tumour necrosis factor-α (TNF-α) biological activity in psoriatic skin lesions. Clin Exp Immunol. 96:146–151. 1994. View Article : Google Scholar : PubMed/NCBI
16	Moorchung N, Vasudevan B, Mani NS and Verma R: Expression of tumor necrosis factor-α and nuclear factor-kappaB/RelA and the pathogenesis of psoriasis. Indian J Pathol Microbiol. 57:205–208. 2014. View Article : Google Scholar : PubMed/NCBI
17	Johansen C, Funding AT, Otkjaer K, Kragballe K, Jensen UB, Madsen M, Binderup L, Skak-Nielsen T, Fjording MS and Iversen L: Protein expression of TNF-alpha in psoriatic skin is regulated at a posttranscriptional level by MAPK-activated protein kinase 2. J Immunol. 176:1431–1438. 2006. View Article : Google Scholar : PubMed/NCBI
18	Sereflican B, Goksugur N, Bugdayci G, Polat M and Haydar Parlak A: Serum visfatin, adiponectin, and tumor necrosis factor alpha (TNF-α) levels in patients with psoriasis and their correlation with disease severity. Acta Dermatovenerol Croat. 24:13–19. 2016.PubMed/NCBI
19	Olteanu R, Zota A and Constantin M: Biosimilars: An update on clinical trials (review of published and ongoing studies). Acta Dermatovenerol Croat. 25:57–66. 2017.PubMed/NCBI
20	Zhu JW, Wu XJ, Lu ZF, Luo D, Cai SQ and Zheng M: Role of VEGF receptors in normal and psoriatic human keratinocytes: Evidence from irradiation with different UV sources. PLoS One. 8:e554632013. View Article : Google Scholar : PubMed/NCBI
21	Kristensen M, Chu CQ, Eedy DJ, Feldmann M, Brennan FM and Breathnach SM: Localization of tumour necrosis factor-alpha (TNF-alpha) and its receptors in normal and psoriatic skin: Epidermal cells express the 55-kD but not the 75-kD TNF receptor. Clin Exp Immunol. 94:354–362. 1993. View Article : Google Scholar : PubMed/NCBI
22	Sidhom E, Pilmane M and Kisis J: Local antimicrobial, protease and cytokine defense systems in psoriatic skin. Indian J Dermatol Venereol Leprol. 82:284–291. 2016. View Article : Google Scholar : PubMed/NCBI
23	Theodorakopoulou E, Yiu ZZ, Bundy C, Chularojanamontri L, Gittins M, Jamieson LA, Motta L, Warren RB and Griffiths CE: Early- and late-onset psoriasis: A cross-sectional clinical and immunocytochemical investigation. Br J Dermatol. 175:1038–1044. 2016. View Article : Google Scholar : PubMed/NCBI
24	Campanati A, Goteri G, Simonetti O, Ganzetti G, Giuliodori K, Giuliano A, Sabato S, Stramazzotti D, Gulini E, Dusi D, et al: Angiogenesis in psoriatic skin and its modifications after administration of etanercept: Videocapillaroscopic, histological and immunohistochemical evaluation. Int J Immunopathol Pharmacol. 22:371–377. 2009. View Article : Google Scholar : PubMed/NCBI
25	Negrei C, Arsene AL, Toderescu CD, Boda D and Ilie M: Acitretin treatment in psoriazis may influence the cell membrane fluidity. Farmacia. 60:767–771. 2012.
26	Simonetti O, Lucarini G, Goteri G, Zizzi A, Biagini G, Lo Muzio L and Offidani A: VEGF is likely a key factor in the link between inflammation and angiogenesis in psoriasis: Results of an immunohistochemical study. Int J Immunopathol Pharmacol. 19:751–760. 2006. View Article : Google Scholar : PubMed/NCBI
27	Flisiak I, Zaniewski P, Rogalska M, Myśliwiec H, Jaroszewicz J and Chodynicka B: Effect of psoriasis activity on VEGF and its soluble receptors concentrations in serum and plaque scales. Cytokine. 52:225–229. 2010. View Article : Google Scholar : PubMed/NCBI
28	Keen MA and Hassan I: Serum prolactin levels in psoriasis and its association with disease activity: A case-control study. Indian J Dermatol. 59:562–566. 2014. View Article : Google Scholar : PubMed/NCBI
29	Kato AM, Gheida SF and El-Bendary AS: Serum level of prolactin in psoriatic patients. EDOJ. 2:12012.
30	Dilmé-Carreras E, Martín-Ezquerra G, Sánchez-Regaña M and Umbert-Millet P: Serum prolactin levels in psoriasis and correlation with cutaneous disease activity. Clin Exp Dermatol. 36:29–32. 2011. View Article : Google Scholar